Do analysts prefer QNCX or SCLX?

Quince Therapeutics presently has a consensus target price of $690.00, indicating a potential upside of 3,833.87%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Quince Therapeutics is more favorable than Scilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quince Therapeutics 2 Sell rating(s) 5 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.20 Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is QNCX or SCLX more profitable?

Quince Therapeutics has a net margin of 0.00% compared to Scilex's net margin of -1,110.17%. Company Net Margins Return on Equity Return on Assets Quince Therapeutics N/A N/A -67.99% Scilex -1,110.17% N/A -143.55%

Does the media refer more to QNCX or SCLX?

In the previous week, Scilex had 8 more articles in the media than Quince Therapeutics. MarketBeat recorded 11 mentions for Scilex and 3 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 0.72 beat Scilex's score of 0.54 indicating that Quince Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quince Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scilex 3 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, ANVS or QNCX?

Annovis Bio is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Annovis Bio N/A N/A -$28.85M -$1.71 N/A Quince Therapeutics N/A N/A -$83.98M -$212.40 N/A

Is ANVS or QNCX more profitable?

Quince Therapeutics' return on equity of 0.00% beat Annovis Bio's return on equity. Company Net Margins Return on Equity Return on Assets Annovis Bio N/A -318.08% -215.47% Quince Therapeutics N/A N/A -67.99%

Does the media prefer ANVS or QNCX?

In the previous week, Annovis Bio had 3 more articles in the media than Quince Therapeutics. MarketBeat recorded 6 mentions for Annovis Bio and 3 mentions for Quince Therapeutics. Annovis Bio's average media sentiment score of 0.88 beat Quince Therapeutics' score of 0.72 indicating that Annovis Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annovis Bio 0 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quince Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer QNCX or XLO?

In the previous week, Xilio Therapeutics had 2 more articles in the media than Quince Therapeutics. MarketBeat recorded 5 mentions for Xilio Therapeutics and 3 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 0.72 beat Xilio Therapeutics' score of 0.38 indicating that Quince Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quince Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xilio Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, QNCX or FLNA?

Cassava Sciences is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quince Therapeutics N/A N/A -$83.98M -$212.40 N/A Cassava Sciences N/A N/A -$90.97M -$1.61 N/A

Is QNCX or FLNA more profitable?

Quince Therapeutics' return on equity of 0.00% beat Cassava Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Quince Therapeutics N/A N/A -67.99% Cassava Sciences N/A -53.90% -34.20%

Does the media prefer QNCX or UPXI?

In the previous week, Quince Therapeutics had 1 more articles in the media than Upexi. MarketBeat recorded 3 mentions for Quince Therapeutics and 2 mentions for Upexi. Upexi's average media sentiment score of 0.93 beat Quince Therapeutics' score of 0.72 indicating that Upexi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quince Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Upexi 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Quince Therapeutics (QNCX) Competitors

$17.54 0.00 (0.00%)

Closing price 07/10/2026 04:00 PM Eastern

Extended Trading

$17.41 -0.13 (-0.74%)

As of 04:10 AM Eastern

Compare

QNCX vs. SCLX, ANVS, XLO, FLNA, and UPXI

Should you buy Quince Therapeutics stock or one of its competitors? MarketBeat compares Quince Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Quince Therapeutics include Scilex (SCLX), Annovis Bio (ANVS), Xilio Therapeutics (XLO), Cassava Sciences (FLNA), and Upexi (UPXI). These companies are all part of the "pharmaceutical products" industry.

How does Quince Therapeutics compare to Scilex?

Quince Therapeutics (NASDAQ:QNCX) and Scilex (NASDAQ:SCLX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

Quince Therapeutics presently has a consensus target price of $690.00, indicating a potential upside of 3,833.87%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Quince Therapeutics is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.20
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Quince Therapeutics has a net margin of 0.00% compared to Scilex's net margin of -1,110.17%.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	N/A	-67.99%
Scilex	-1,110.17%	N/A	-143.55%

30.8% of Quince Therapeutics shares are owned by institutional investors. Comparatively, 69.7% of Scilex shares are owned by institutional investors. 7.1% of Quince Therapeutics shares are owned by insiders. Comparatively, 4.5% of Scilex shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Quince Therapeutics has higher earnings, but lower revenue than Scilex. Scilex is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$212.40	N/A
Scilex	$30.25M	2.66	-$358.73M	-$40.47	N/A

In the previous week, Scilex had 8 more articles in the media than Quince Therapeutics. MarketBeat recorded 11 mentions for Scilex and 3 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 0.72 beat Scilex's score of 0.54 indicating that Quince Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quince Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scilex	3 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Quince Therapeutics has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market. Comparatively, Scilex has a beta of 1.66, meaning that its share price is 66% more volatile than the broader market.

Summary

Quince Therapeutics beats Scilex on 10 of the 15 factors compared between the two stocks.

How does Quince Therapeutics compare to Annovis Bio?

Annovis Bio (NYSE:ANVS) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

Annovis Bio presently has a consensus target price of $11.67, suggesting a potential upside of 526.23%. Quince Therapeutics has a consensus target price of $690.00, suggesting a potential upside of 3,833.87%. Given Quince Therapeutics' higher possible upside, analysts clearly believe Quince Therapeutics is more favorable than Annovis Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.20

15.8% of Annovis Bio shares are held by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are held by institutional investors. 20.8% of Annovis Bio shares are held by company insiders. Comparatively, 7.1% of Quince Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Annovis Bio has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market. Comparatively, Quince Therapeutics has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market.

Annovis Bio is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.71	N/A
Quince Therapeutics	N/A	N/A	-$83.98M	-$212.40	N/A

Quince Therapeutics' return on equity of 0.00% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-318.08%	-215.47%
Quince Therapeutics	N/A	N/A	-67.99%

In the previous week, Annovis Bio had 3 more articles in the media than Quince Therapeutics. MarketBeat recorded 6 mentions for Annovis Bio and 3 mentions for Quince Therapeutics. Annovis Bio's average media sentiment score of 0.88 beat Quince Therapeutics' score of 0.72 indicating that Annovis Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annovis Bio	0 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quince Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Annovis Bio and Quince Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Quince Therapeutics compare to Xilio Therapeutics?

Quince Therapeutics (NASDAQ:QNCX) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

30.8% of Quince Therapeutics shares are held by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are held by institutional investors. 7.1% of Quince Therapeutics shares are held by company insiders. Comparatively, 7.5% of Xilio Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Quince Therapeutics currently has a consensus price target of $690.00, suggesting a potential upside of 3,833.87%. Xilio Therapeutics has a consensus price target of $28.00, suggesting a potential upside of 207.02%. Given Quince Therapeutics' higher probable upside, equities analysts clearly believe Quince Therapeutics is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.20
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Quince Therapeutics has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -58.52%. Quince Therapeutics' return on equity of 0.00% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	N/A	-67.99%
Xilio Therapeutics	-58.52%	-151.42%	-27.61%

Xilio Therapeutics has higher revenue and earnings than Quince Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$212.40	N/A
Xilio Therapeutics	$43.77M	1.37	-$35.04M	-$3.55	N/A

Quince Therapeutics has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.14, meaning that its share price is 114% less volatile than the broader market.

In the previous week, Xilio Therapeutics had 2 more articles in the media than Quince Therapeutics. MarketBeat recorded 5 mentions for Xilio Therapeutics and 3 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 0.72 beat Xilio Therapeutics' score of 0.38 indicating that Quince Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quince Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xilio Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Xilio Therapeutics beats Quince Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Quince Therapeutics compare to Cassava Sciences?

Quince Therapeutics (NASDAQ:QNCX) and Cassava Sciences (NASDAQ:FLNA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

Quince Therapeutics' return on equity of 0.00% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	N/A	-67.99%
Cassava Sciences	N/A	-53.90%	-34.20%

Cassava Sciences is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$212.40	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A

Quince Therapeutics currently has a consensus price target of $690.00, suggesting a potential upside of 3,833.87%. Cassava Sciences has a consensus price target of $5.00, suggesting a potential upside of 323.73%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Quince Therapeutics is more favorable than Cassava Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.20
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Quince Therapeutics had 2 more articles in the media than Cassava Sciences. MarketBeat recorded 3 mentions for Quince Therapeutics and 1 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 1.87 beat Quince Therapeutics' score of 0.72 indicating that Cassava Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Quince Therapeutics	Positive
Cassava Sciences	Very Positive

Quince Therapeutics has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.73, indicating that its share price is 173% less volatile than the broader market.

30.8% of Quince Therapeutics shares are held by institutional investors. Comparatively, 38.0% of Cassava Sciences shares are held by institutional investors. 7.1% of Quince Therapeutics shares are held by company insiders. Comparatively, 4.6% of Cassava Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Quince Therapeutics beats Cassava Sciences on 10 of the 14 factors compared between the two stocks.

How does Quince Therapeutics compare to Upexi?

Quince Therapeutics (NASDAQ:QNCX) and Upexi (NASDAQ:UPXI) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.

Upexi has higher revenue and earnings than Quince Therapeutics. Upexi is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$212.40	N/A
Upexi	$15.81M	4.13	-$13.68M	-$0.62	N/A

Quince Therapeutics has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, Upexi has a beta of -0.29, indicating that its share price is 129% less volatile than the broader market.

Quince Therapeutics presently has a consensus target price of $690.00, indicating a potential upside of 3,833.87%. Upexi has a consensus target price of $8.10, indicating a potential upside of 875.90%. Given Quince Therapeutics' higher probable upside, equities research analysts clearly believe Quince Therapeutics is more favorable than Upexi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.20
Upexi	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Quince Therapeutics has a net margin of 0.00% compared to Upexi's net margin of -874.00%. Quince Therapeutics' return on equity of 0.00% beat Upexi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	N/A	-67.99%
Upexi	-874.00%	-66.70%	-19.56%

In the previous week, Quince Therapeutics had 1 more articles in the media than Upexi. MarketBeat recorded 3 mentions for Quince Therapeutics and 2 mentions for Upexi. Upexi's average media sentiment score of 0.93 beat Quince Therapeutics' score of 0.72 indicating that Upexi is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quince Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Upexi	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

30.8% of Quince Therapeutics shares are held by institutional investors. Comparatively, 5.7% of Upexi shares are held by institutional investors. 7.1% of Quince Therapeutics shares are held by insiders. Comparatively, 9.0% of Upexi shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Quince Therapeutics beats Upexi on 8 of the 15 factors compared between the two stocks.

Get Quince Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QNCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QNCX vs. The Competition

Export

Metric	Quince Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$17.19M	$3.70B	$6.89B	$12.64B
Dividend Yield	N/A	2.20%	2.68%	8.01%
P/E Ratio	-0.08	21.64	27.36	24.52
Price / Sales	N/A	217.49	498.05	83.23
Price / Cash	N/A	61.98	29.24	49.38
Price / Book	-0.14	8.70	11.13	6.43
Net Income	-$83.98M	$23.83M	$3.59B	$331.05M
7 Day Performance	3.30%	-1.11%	-0.99%	-1.34%
1 Month Performance	-6.07%	8.71%	4.50%	0.52%
1 Year Performance	-95.18%	55.85%	29.76%	22.23%

Quince Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QNCX Quince Therapeutics	2.8646 of 5 stars	$17.54 flat	$690.00 +3,833.9%	-95.2%	$17.19M	N/A	N/A	60	Short Interest Decrease
SCLX Scilex	0.8056 of 5 stars	$7.80 +9.7%	N/A	+46.7%	$60.37M	$30.25M	N/A	80
ANVS Annovis Bio	3.4564 of 5 stars	$1.86 +8.0%	$13.50 +626.6%	-31.5%	$59.59M	N/A	N/A	3
XLO Xilio Therapeutics	2.0979 of 5 stars	$9.27 +2.4%	$28.00 +202.0%	-11.3%	$59.51M	$43.77M	N/A	70	High Trading Volume
FLNA Cassava Sciences	2.2059 of 5 stars	$1.22 +1.7%	$5.00 +309.8%	-44.6%	$58.94M	N/A	N/A	20	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QNCX) was last updated on 7/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Quince Therapeutics (QNCX) Competitors

QNCX vs. SCLX, ANVS, XLO, FLNA, and UPXI

How does Quince Therapeutics compare to Scilex?

Summary

How does Quince Therapeutics compare to Annovis Bio?

Summary

How does Quince Therapeutics compare to Xilio Therapeutics?

Summary

How does Quince Therapeutics compare to Cassava Sciences?

Summary

How does Quince Therapeutics compare to Upexi?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNCX vs. The Competition

Quince Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Quince Therapeutics (QNCX) Competitors

QNCX vs. SCLX, ANVS, XLO, FLNA, and UPXI

How does Quince Therapeutics compare to Scilex?

Do analysts prefer QNCX or SCLX?

Is QNCX or SCLX more profitable?

Do institutionals and insiders believe in QNCX or SCLX?

Which has higher earnings and valuation, QNCX or SCLX?

Does the media refer more to QNCX or SCLX?

Which has more volatility and risk, QNCX or SCLX?

Summary

How does Quince Therapeutics compare to Annovis Bio?

Do analysts prefer ANVS or QNCX?

Do institutionals and insiders have more ownership in ANVS or QNCX?

Which has more risk & volatility, ANVS or QNCX?

Which has higher valuation and earnings, ANVS or QNCX?

Is ANVS or QNCX more profitable?

Does the media prefer ANVS or QNCX?

Summary

How does Quince Therapeutics compare to Xilio Therapeutics?

Do institutionals & insiders have more ownership in QNCX or XLO?

Do analysts recommend QNCX or XLO?

Is QNCX or XLO more profitable?

Which has higher valuation & earnings, QNCX or XLO?

Which has more volatility and risk, QNCX or XLO?

Does the media prefer QNCX or XLO?

Summary

How does Quince Therapeutics compare to Cassava Sciences?

Is QNCX or FLNA more profitable?

Which has preferable valuation and earnings, QNCX or FLNA?

Do analysts prefer QNCX or FLNA?

Does the media refer more to QNCX or FLNA?

Which has more volatility and risk, QNCX or FLNA?

Do insiders and institutionals hold more shares of QNCX or FLNA?

Summary

How does Quince Therapeutics compare to Upexi?

Which has stronger earnings & valuation, QNCX or UPXI?

Which has more volatility & risk, QNCX or UPXI?

Do analysts rate QNCX or UPXI?

Is QNCX or UPXI more profitable?

Does the media prefer QNCX or UPXI?

Do institutionals & insiders hold more shares of QNCX or UPXI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNCX vs. The Competition

Quince Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools